NCT Number: NCT00002171
A Study of Viracept in HIV-Positive Women
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.
Looking for future studies?
Notify MeKey information
Conditions
Age range
13 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 2
Primary location
Univ of Alabama at Birmingham, Birmingham, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients must have:
- HIV infection.
- CD4 T cell count <= 400 cells/mm3.
Exclusion criteria
Prior Medication:
Excluded:
- Prior therapy or less than 1 month of therapy with d4T and/or 3TC.
- Prior protease inhibitor therapy.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Agouron Pharmaceuticals
Industry
Registry information
Official study title
A Phase II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Viracept in Combination With Antiretroviral Therapy in HIV Positive Women With <= 1 Month of Prior Treatment With d4T and/or 3TC
Important dates
- First posted
- Aug 31, 2001
- Registry last updated
- Jun 24, 2005
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study Among People Living With HIV and Their Health Professionals of Associated Factors of Resilience to Self-stigma
NCT05149001
Behavior, Blood-Borne Infections
Aix-en-Provence, France
View Trial DetailsSkills to Empower Affirmative Men
NCT05732675
Behavior, Bisexuality
Ho Chi Minh City, Vietnam
View Trial DetailsImplementation and Assessment of a Medication Therapy Management Program in HIV Patients at High Risk of Adverse Drug Events at Khartoum, Sudan
NCT07750834
Acquired Immunodeficiency Syndrome, Behavior
Khartoum, Omdurman, Sudan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
NCT06012136
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Las Vegas, Nevada, United States
View Trial Details